Content

Past Issues

Download Magazine

Search

Subscribe

  • This field is for validation purposes and should be left unchanged.

Welcome!

Welcome!

Error: No layouts found

In March, Jonathan E. Alpert, M.D., Ph.D., joined Einstein and Montefiore as a professor and university chair of the department of psychiatry and behavioral sciences. He also assumed the Dorothy and Marty Silverman Chair in Psychiatry at Einstein. He succeeds T. Byram Karasu, M.D., who led the department for nearly 25 years.

Dr. Alpert previously served as vice chair for clinical services in psychiatry at Massachusetts General Hospital (MGH), where he led the behavioral health executive committee. He directed the depression clinical and research programs at MGH and was the first recipient of the Joyce R. Tedlow Chair in the field of depression studies at Harvard Medical School.

Dr. Alpert has written more than 200 publications on topics including pharmacological and other innovative approaches to treatment-resistant major depressive disorder; depressive subtypes and biomarkers; drug metabolism and drug interactions; ethical issues in the design and conduct of human studies; behavioral health integration; and medical education.

He has received numerous awards for teaching, mentorship and clinical excellence, serves on the board of the National Network of Depression Centers and is a distinguished fellow of the American Psychiatric Association.

Dr. Alpert received his M.D. from the Yale University School of Medicine and his Ph.D. in behavioral pharmacology from the University of Cambridge, United Kingdom, where he was a Marshall Scholar. He completed residencies at Harvard-Boston Children’s Hospital (pediatrics) and at Harvard-McLean Hospital (psychiatry) before joining the Harvard-MGH psychiatry faculty in 1992.

More From Einstein

Class of 2024 Celebrates Match Day
Einstein Community Enjoys Pi Day
Graduate Students Win Marmur Award
Empowering Einstein Women in Science
Einstein Secures $192M in NIH Grants
Training the Next Cancer Researchers
Bringing a Novel Drug to Market
A Promise to Rwandan Genocide Survivors